Skip to main content

Table 4 Cumulative incidence of revision at 1 and 5 years’ follow-up and effect of comorbidities from the Elixhauser index on the risk of revision in Total Hip Arthroplasty (THA)

From: Impact of comorbidity on the short- and medium-term risk of revision in total hip and knee arthroplasty

 

1 year follow-up

5 years’ follow-up

Np

Nr

Incidence (95% CI)

SHR (95%CI)

p value

Np

Nr

incidence (95% CI)

SHR (95% CI)

P value

Burden of comorbidity

    

0.021

    

0.030

 0 comorbidities

6270

61

0.92 (0.71–1.18)

1.00

 

3391

79

2.45 (2.06–2.88)

1.00

 

 1 comorbidity

5501

70

1.17 (0.92–1.47)

1.29 (0.91–1.84)

 

2717

56

2.33 (1.95–2.77)

1.09 (0.85–1.40)

 

 > =2 comorbidities

4388

68

1.39 (1.10–1.76)

1.51 (1.05–2.15)

 

1927

53

2.94 (2.44–3.50)

1.32 (1.03–1.71)

 

Uncomplicated hypertension

7161

100

1.29 (1.06–1.56)

1.21 (0.91–1.62)

0.189

3448

78

2.60 (2.23–3.00)

1.12 (0.91–1.38)

0.276

Uncomplicated diabetes

1949

31

1.43 (0.99–2.00)

1.30 (0.89–1.92)

0.177

901

24

2.91 (2.21–3.76)

1.25 (0.94–1.67)

0.130

Obesity

1072

23

1.90 (1.24–2.79)

1.81 (1.17–2.80)

0.007

479

21

4.39 (3.21–5.84)

1.80 (1.31–2.47)

< 0.001

Depression

1030

15

1.32 (0.77–2.12)

1.16 (0.69–1.97)

0.575

455

16

3.35 (2.30–4.72)

1.28 (0.89–1.85)

0.185

Chronic pulmonary disease

1270

20

1.42 (0.90–2.16)

1.32 (0.83–2.07)

0.240

564

11

2.52 (1.74–3.54)

1.07 (0.74–1.54)

0.729

Hypothyroidism

668

8

1.08 (0.51–2.05)

0.92 (0.45–1.90)

0.825

262

6

2.44 (1.36–4.05)

0.87 (0.51–1.50)

0.625

Deficiency anemia

421

6

1.28 (0.54–2.65)

1.14 (0.51–2.53)

0.752

187

6

2.91 (1.58–4.90)

1.26 (0.71–2.23)

0.421

Renal failure

323

4

1.04 (0.35–2.51)

0.85 (0.31–2.33)

0.753

100

2

1.84 (0.75–3.84)

0.84 (0.39–1.89)

0.667

Hypertension with complications

254

1

0.33 (0.03–1.72)

0.27 (0.04–1.94)

0.192

69

1

0.75 (1.50–2.51)

0.36 (0.09–1.45)

0.151

Valvular disease

259

2

0.69 (0.14–2.31)

0.55 (0.14–2.20)

0.399

113

0

NR

NC

NC

Rheumatoid arthritis

249

3

1.06 (0.30–2.87)

0.93 (0.30–2.90)

0.898

101

4

2.88 (1.27–5.62)

1.16 (0.55–2.45)

0.690

Other neurological disorders

212

3

1.29 (0.36–3.49)

1.17 (0.38–3.67)

0.780

88

2

2.23 (0.84–4.85)

1.07 (0.44–2.59)

0.882

Liver disease

245

2

0.71 (0.14–2.38)

0.71 (0.18–2.87)

0. 630

106

5

3.42 (1.68–6.69)

1.23 (0.59–2.59)

0.581

Congestive heart failure

131

2

1.36 (0.27–4.42)

1.10 (0.27–4.51)

0. 895

52

0

NR

NC

NC

Peripheral vascular disorders

143

3

1.85 (0.51–4.93)

1.73 (0.54–5.40)

0. 349

67

4

5.39 (2.31–10.38)

2.24 (1.06–4.74)

0.034

Solid tumor

87

1

1.08 (0.09–5.25)

0.87 (0.12–6.13)

0. 885

40

1

2.20 (0.42–6.97)

1.01 (0.25–4.06)

0.987

Diabetes with complications

55

0

NR

NC

NC

22

0

NR

NC

NC

Coagulopathy

71

0

NR

NC

NC

37

0

NR

NC

NC

Blood loss anemia

65

0

NR

NC

NC

39

0

NR

NC

NC

Fluid and electrolyte disorders

113

1

0.80 (0.07–3.99)

0.68 (0.10–4.81)

0.701

47

1

1.67 (0.32–5.36)

0.77 (0.19–3.10)

0.715

Alcohol abuse

110

2

1.69 (0.33–5.42)

1.81 (0.47–7.23)

0.404

48

0

NR

NC

NC

Psychoses

65

2

2.72 (0.52–8.49)

2.62 (0.65–10.63)

0.176

17

2

5.88 (1.89–13.23)

2.77 (1.03–7.49)

0.044

Paralysis

35

1

2.63 (0.20–11.79)

2.46 (0.36–16.87)

0.375

14

1

5.58 (1.00–16.41)

2.55 (0.63–10.28)

0.188

Pulmonary circulation disorders

17

0

NR

NC

NC

9

0

NR

NC

NC

Lymphoma

16

1

6.25 (0.41–24.69)

5.32 (0.75–37.33)

0.092

4

0

NR

NC

NC

Peptic ulcer disease

3

0

NR

NC

NC

3

0

NR

NC

NC

Drug abuse

23

0

NR

NC

NC

10

0

NR

NC

NC

Metastatic cancer

5

1

10.0 (0.57–35.81)

12.23 (1.46–102.46)

0.021

3

0

NR

NC

NC

Weight loss

6

0

NR

NC

NC

2

0

NR

NC

NC

AIDS

14

1

7,14 (0.45–27.52)

8.17 (0.82–56.81)

0.089

6

0

NR

NC

NC

  1. np number of primary procedures at 1 and 5 years’ follow-up, nr number of revision procedures since the primary operation (from the beginning to 1 year and from 1 year to 5 years, at follow-up), SHR Subhazard ratio from competing risks models adjusted for sex, age, year of intervention, fixation type and type of hospital, NR no revisions undergone from 1 to 5 years’ follow-up, NC Not calculable
  2. Incidence (95%CI): cumulative incidence of revision considering patient death as a competing event and the 95% Confidence Interval
  3. Variance inflation tests < 4 for all models